Health & Fitness
Tue, January 10, 2012Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Tue, January 3, 2012Mon, January 2, 2012Sat, December 31, 2011Fri, December 30, 2011Thu, December 29, 2011Wed, December 28, 2011Tue, December 27, 2011Mon, December 26, 2011Fri, December 23, 2011Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January 9
Published in Health and Fitness on Wednesday, January 4th 2012 at 5:10 GMT by Market Wire
Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January... -- BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ --
Unigene to Present at Biotech Showcasea" 2012 in San Francisco on January 9
BOONTON, N.J., Jan. 4, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE),a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced that Ashleigh Palmer, President and Chief Executive Officer, will present a corporate overview at the Biotech Showcase™ 2012 in San Francisco, CA on Monday, January 9, 2012 at 11:30 a.m. PT (2:30 p.m. ET). Mr. Palmer's presentation will include an overview of Unigene's industry-leading oral peptide delivery platform and pipeline along with the Company's business outlook and expected milestones for 2012.
A live webcast of the presentation will be available by visiting the Investors and Media section under the Events tab of the Unigene web site, [ http://www.unigene.com ]. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's web site for 30 days.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
[ jthomas@unigene.com ]
Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / June Gregg
212-827-0020
[ jrando@tiberend.com ] / [ jgregg@tiberend.com ]
SOURCE Unigene Laboratories, Inc.
[ Back to top ] RELATED LINKS
[ http://www.unigene.com ]
